COAGULATION DISTURBANCES

Thesis

IN SARCOIDOSIS

Submitted For Partial Fulfiliment Of Master Degree In Biochemistry

By

Amany Salah El-Dian Elwakkad M.B.B. Ch.

A.5

Supervisors

Prof. Dr. Salah El-Din Zaki Eid
Professor of Biochemistry
Faculty of Medicine
Ain Shams University

40,57

Prof. Dr. El-Said El-Hilaly
Professor of Chest Disease
Faculty of Medicine
Ain Shams University

Dr. Hanaa El-Tayb Naser
Assisstant Professor of Biochemistry
Faculty of Medicine
Ain Shams University

1993





ACKNOWLEDGEMENT

First and foremost, thanks are due to God for all the blessings with which are endowed.

I am greatly honoured to express my profound gratitude to Prof. Dr. Salah El-Din Zaki Eid, Professor of Biochemistry and Dean of Medicine, Ain Shams University, Fo suggesting the subject of this thesis, for providing the facilities to carry out this work and for his enthusiastic supervision and fatherly encouragement all throughout the course of this study.

I would like to express my deepest thanks to Prof. Dr. El-Said El-Hilaly, Professor and Head of the Department of Chest Disease, Faculty of Medicine Ain Shams University for his great help in selecting and supplying the material of this work and for his continuous guidance in the clinical part of my study.

My deep appreciation and thanks to Prof. Dr. Nawal Abdo Ziada Professor of Biochemistry and Head of Biochemistry Department, Faculty of Medicine Ain Shams University for reading and revising the manuscript and for whome no words of gratitude are sufficient.

I am indeed thankful to Dr. Hanaa El-Tayeb Assistant Professor of Biochemistry Department, Faculty of Medicine Ain Shams University who gave me most of her time helping in carrying out the practical work and revisings the manuscript. Her friendly and scientific advice and her enthusiastic help are beyond acknowledgement.

My deep appreciation and thanks to Prof. Dr. Raifat Awad Allah, Professor of Biochemistry, Basic Medical Science Department, National Research Centre Dokki, Cairo for his valuable scientific advices and guidance.

I would like to express my sincere gratitude and deep appreciation to **Dr. Nour El-Hoda**, **Abbasia Chest Hospital** for supplying us with the material of this work and her great sincerity.

CONTENTS

Introduction and Aim of the work	1
Review of literature	3
Sarcoidosis	3
Blood clotting	25
Platelets	45
Methods and Materials	62
Estimation of Agniotensin Converting enzyme	63
Estimation of Recalcification Time	67
Estimation of Cloting Time for Plasma Deficient	
in Factor II, V, IX, X	68
Estimation of Fibrinogen Concentration	77
Estimation of Fibrinogen Degradation Product	79
Estimation of Platelet Aggregation	81
Induced by ADP and Collagen Statistics	85
Results	88
Discussion	119
Summary	125
References	127
Arabic Summary	138

LIST OF TABLES

	Page
Table (1):	91
Represents the concentration of angiotensin	converting
enzyme for the normal control group	
Table (2):	93
Represents the Concentration of Angiotensin C	Converting
Enzyme in Patient group.	
Table (3):	94
Represents the Recalcification Time for Norma	al Control
Group	
Table (4) :	95
Represents the Recalcification Time for Patien	t Group
Table (5):	97
Represents the clotting time for normal con-	trol group
using plasma deficient in factor II, V, IX, X	
Table (6) :	99
It represents the results of clotting time for	or patients
group using plasma deficient in factor II, V, I	X, X.

Table (7) :

101

A comparison table for recalcification time and clotting time assayed by plasma deficient in factor II, V, IX,X, between the normal control group and the patient group the data are represented as Mean \pm standard deviation.

Table (8) :

103

Gives the results of fibrinogen concentration for the normal control group.

Table (9) :

104

Gives the results of fibrinogen concentration for the patient group.

Table (10):

106

Shows the results of fibrinogen degrada tion product assay for the normal control group.

Tble (11) :

107

Shows the results of fibrinogen degradation product assay for the patient group.

Table (12) :

109

Compare the results for fibrinogen and fibrinogen egradation product between normal group and Patient group.

Page

Table (13):

110

Represents the effect of addition of (20 μ /ml) ADP and (50 μ /ml) collagen on normal human platelets aggregation.

Table (14):

111

Represents the effect of addition of (20 μ /ml) ADP and (50 μ /ml) collagen on patient platelets aggregation .

Table (15):

113

Shows a comparison of human platelets ggregation after addition of (20 μ /ml) ADP, (50 μ /ml) collagen between normal human platelets and patient human plate lets

LIST OF FIGURES

	_
	Page
Fig. 1:	7
The pathogenesis of granuloma formatio	n
Fig.2:	31
Mechanism of activation of factor IX by	factor
XIa.	
Fig. 3:	34
Mechanism of activation of bovine factor	х сно
refers to carbohydrate.	
Fig. 4:	39
The hypothetical model of the prothrombinase con	nplex.
Fig. 5:	44
Diagramatic representation of the fib	rinogen
molecule and its conversion to the soft clot fibrin	l .
Fig. 6:	61
The blood clotting cascade in humans show	ing the
division of its primary stages into the so-called i	intrinsic
and extrinsic pathways.	

Page

Fig. 7:

115

Represents the effect of addition of (20 μ /ml) of ADP on normal human platelets aggregation.

Fig. 8:

116

Represents the effect of addition of (20 $\,\mu/ml$) of ADP on patient human platelets aggregation.

Fig. 9:

117

Represents the effect of addition of (50 μ /ml) of collagen on normal human platelets aggregation.

Fig. 10:

118

Represents the effect of addition of (50 $\,\mu/ml$) of collagen on patient platelets aggregation.

ABREVIATION

Pt Patient

PA Plasminogen activator

PC Procoagulant activities

BAL Branches alvealar lavage

ACE Angiotensin converting enzyme

IL Interleukin

IF Ierferon

MCF Monocyte chemotactic factor

MAF Macrophage activating factor

MIF Macrophage inhibition factor

AMDF Alveolar macrophage Divided groth factor

SD Standard deviation

Alb Albumin

SACE Serum ACE

SAlb Serum Alb

LACE Lavage ACE

LAlb Lavage Alb

DIC Disseminate dintravascular coagulation

ARDS Adult respiratory distress

ILD Syndrome Interstitial lung disease

BALF Fluid of BAL

LAM Lung alvealar macrophages

COLD Chronic obstructive lung disease

IPF Idiopathic pulmonary fibrosis

AIDS Acquired immunodeficiency syndroms

TPL Tissue thromoplastin lung

FPA Fibrino peptide A

FDP Fibrin degradation products

SDS Sodium dodecyl sulphate

GLA r-Carboxy glutamate residues.

ArG-Gly Arginine - glycine.

FSF Fibrin stabilizing factor

IMPS Intra membranous particles

ADP Adenosine diphosphate

SCCS Surface connected corralicular system

VWF Von willebrand factor

ATP Adenosin triphosphate

DTS Dense tubular system

CMS Canalicular membrane system

CAMP Cyclic adenosine monophosphate

TXA₂ Thromboxane A₂

PGG₂ Prostaglandin G₂

PGH₂ Prostaglandin H₂

12-HPETE 12-hydroperoxyeicosatetraenoic

12-HETE 12-hydroxyeicosatetaen acid

EC Enzyme activity

PRP Platelet rich plasma

PPP Platelet poor plasma

INTRODUCTION & AIM OF OF WORK